Blood Res.  2023 Dec;58(4):242-245. 10.5045/br.2023.2023194.

Lenalidomide as a treatment for patients with AL amyloidosis and cardiac involvement

• Jang SY
• Byun JM
• Yoon SS
• Paeng JC
• Lee SP
• Koh Y

• KMID: 2550208
• DOI: http://doi.org/10.5045/br.2023.2023194

Reference

1. Merlini G. 2017; AL amyloidosis: from molecular mechanisms to targeted therapies. Hematology Am Soc Hematol Educ Program. 2017:1–12. DOI: 10.1182/asheducation-2017.1.1. PMID: 29222231. PMCID: PMC6142527.

2. Kastritis E, Palladini G, Minnema MC, et al. 2021; Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 385:46–58. DOI: 10.1056/NEJMoa2028631. PMID: 34192431.

3. Roccatello D, Fenoglio R, Sciascia S, et al. 2020; CD38 and anti-CD38 monoclonal antibodies in AL amyloidosis: targeting plasma cells and beyond. Int J Mol Sci. 21:4129. DOI: 10.3390/ijms21114129. PMID: 32531894. PMCID: PMC7312896. PMID: 41bf3818d5ba4b36b0615acd518994ea.

4. Lee SP, Suh HY, Park S, et al. 2020; Pittsburgh B compound positron emission tomography in patients with AL cardiac amyloidosis. J Am Coll Cardiol. 75:380–90. DOI: 10.1016/j.jacc.2019.11.037. PMID: 32000949.

5. Brenner DA, Jain M, Pimentel DR, et al. 2004; Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res. 94:1008–10. DOI: 10.1161/01.RES.0000126569.75419.74. PMID: 15044325.

6. Lachmann HJ, Gallimore R, Gillmore JD, et al. 2003; Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 122:78–84. DOI: 10.1046/j.1365-2141.2003.04433.x. PMID: 12823348.

7. Palladini G, Dispenzieri A, Gertz MA, et al. 2012; New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 30:4541–9. DOI: 10.1200/JCO.2011.37.7614. PMID: 23091105.

8. Choi YJ, Koh Y, Lee HJ, et al. 2022; Independent prognostic utility of ¹¹C-pittsburgh compound B PET in patients with light-chain cardiac amyloidosis. J Nucl Med. 63:1064–9. DOI: 10.2967/jnumed.121.263033. PMID: 34916248. PMCID: PMC9258564.

9. Gertz MA, Comenzo R, Falk RH, et al. 2005; Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 79:319–28. DOI: 10.1002/ajh.20381. PMID: 16044444.

10. Dispenzieri A, Dingli D, Kumar SK, et al. 2010; Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol. 85:757–9. DOI: 10.1002/ajh.21822. PMID: 20872958. PMCID: PMC3691013.

11. Hegenbart U, Bochtler T, Benner A, et al. 2017; Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up. Haematologica. 102:1424–31. DOI: 10.3324/haematol.2016.163246. PMID: 28522573. PMCID: PMC5541875.

12. Cibeira MT, Oriol A, Lahuerta JJ, et al. 2015; A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis. Br J Haematol. 170:804–13. DOI: 10.1111/bjh.13500. PMID: 25974382.

13. Palladini G, Sachchithanantham S, Milani P, et al. 2015; A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 126:612–5. DOI: 10.1182/blood-2015-01-620302. PMID: 25987656.

14. Dimopoulos MA, Oriol A, Nahi H, et al. 2016; Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 375:1319–31. DOI: 10.1056/NEJMoa1607751. PMID: 27705267.